Allworth Financial LP Acquires 2,359 Shares of Xencor, Inc. (NASDAQ:XNCR)

Allworth Financial LP grew its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 29,487.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,367 shares of the biopharmaceutical company’s stock after buying an additional 2,359 shares during the period. Allworth Financial LP’s holdings in Xencor were worth $50,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. BluePath Capital Management LLC bought a new position in Xencor during the 3rd quarter worth $31,000. China Universal Asset Management Co. Ltd. increased its position in Xencor by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 756 shares during the period. Tower Research Capital LLC TRC increased its position in Xencor by 48.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 795 shares during the period. Point72 Asset Management L.P. bought a new position in Xencor during the 4th quarter worth $73,000. Finally, Lazard Asset Management LLC increased its position in Xencor by 203.0% during the 1st quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 3,005 shares during the period.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 54,108 shares of Xencor stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Bassil I. Dahiyat sold 12,528 shares of Xencor stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the sale, the chief executive officer now directly owns 300,097 shares of the company’s stock, valued at $7,031,272.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 54,108 shares of Xencor stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares in the company, valued at $3,133,261.50. The disclosure for this sale can be found here. Insiders have sold 101,351 shares of company stock valued at $2,152,417 over the last ninety days. 4.97% of the stock is owned by corporate insiders.

Xencor Stock Performance

NASDAQ:XNCR opened at $20.48 on Friday. The stock’s 50-day simple moving average is $22.21 and its 200 day simple moving average is $20.40. The firm has a market capitalization of $1.25 billion, a PE ratio of -9.75 and a beta of 0.76. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a twelve month low of $16.49 and a twelve month high of $30.21.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67). The business had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The business’s quarterly revenue was up 106.9% compared to the same quarter last year. During the same period last year, the business earned ($0.20) earnings per share. On average, analysts anticipate that Xencor, Inc. will post -3.25 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. BMO Capital Markets lowered their price objective on Xencor from $38.00 to $34.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Mizuho reduced their target price on Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 22nd. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Wedbush reduced their target price on Xencor from $36.00 to $34.00 and set an “outperform” rating on the stock in a report on Wednesday, February 28th. Finally, Piper Sandler reissued a “neutral” rating and set a $24.00 target price (down from $37.00) on shares of Xencor in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.